Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Currie

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
The American Journal of Gastroenterology|December 23, 2008
Pilot study on the effect of linaclotide in patients with chronic constipationJeffrey M Johnston, Caroline B Kurtz, Douglas A Drossman, et al.
Hypertension (Dallas, Tex. : 1979)|March 18, 2009
The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomersNicholas G Moss, Dorothy A Riguera, Robert M Solinga, et al.
Gastroenterology|August 31, 2010
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipationJeffrey M Johnston, Caroline B Kurtz, James E Macdougall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2013
Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipationSatish S C Rao, Eamonn M M Quigley, Steven J Shiff, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 10, 2003
A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmaticsTrevor T Hansel, Sergei A Kharitonov, Louise E Donnelly, et al.
Clinical Pharmacology in Drug Development|November 14, 2018
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy SubjectsJohn P Hanrahan, James D Wakefield, Phebe J Wilson, et al.
Gastroenterology|February 25, 2020
IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized TrialMichael F Vaezi, Ronnie Fass, Nimish Vakil, et al.
American Journal of Physiology. Renal Physiology|September 1, 2020
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cellsGuang Liu, Courtney M Shea, Juli E Jones, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysisJudy W Nee, Jeffrey M Johnston, Elizabeth P Shea, et al.
Gastroenterology|September 15, 2007
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndromeViola Andresen, Michael Camilleri, Irene A Busciglio, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
The American Journal of Gastroenterology|December 23, 2008
Pilot study on the effect of linaclotide in patients with chronic constipationJeffrey M Johnston, Caroline B Kurtz, Douglas A Drossman, et al.
Hypertension (Dallas, Tex. : 1979)|March 18, 2009
The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomersNicholas G Moss, Dorothy A Riguera, Robert M Solinga, et al.
Gastroenterology|August 31, 2010
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipationJeffrey M Johnston, Caroline B Kurtz, James E Macdougall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2013
Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipationSatish S C Rao, Eamonn M M Quigley, Steven J Shiff, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 10, 2003
A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmaticsTrevor T Hansel, Sergei A Kharitonov, Louise E Donnelly, et al.
Clinical Pharmacology in Drug Development|November 14, 2018
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy SubjectsJohn P Hanrahan, James D Wakefield, Phebe J Wilson, et al.
Gastroenterology|February 25, 2020
IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized TrialMichael F Vaezi, Ronnie Fass, Nimish Vakil, et al.
American Journal of Physiology. Renal Physiology|September 1, 2020
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cellsGuang Liu, Courtney M Shea, Juli E Jones, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysisJudy W Nee, Jeffrey M Johnston, Elizabeth P Shea, et al.
Gastroenterology|September 15, 2007
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndromeViola Andresen, Michael Camilleri, Irene A Busciglio, et al.
Pageof 5